Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. Also provided is a preparation method for the compounds. Also provided is a combination therapy including the compounds in combination with another targeted drug composition or another drug. The optimised combination therapy has a cooperative effect, inhibits the existence of a tumour better than a single targeted drug, and causes certain tumours to completely disappear. The optimised combination therapy treats drug resistance and cancer recurrence of a tumour better than a single targeted drug, and the treatment cycle is shorter. The present invention also relates to a combined compound and a pharmaceutical preparation wherein said combined compound acts as an active ingredient, said pharmaceutical preparation being safer at a lower dosage and having a cooperative effect efficacy. Also provided is a method of using the compounds and a preparation thereof to treat and inhibit an autoimmune disease or illness, a heterogeneous autoimmune disease or illness, an inflammatory disease, a cancer or an illness.Se proporciona una serie de nuevos compuestos de pirazolopirimidina sustituidos con poli-fluoro o sales. Los compuestos son inhibidores de tirosina quinasa de Bruton (BTK)； los compuestos tienen mejor selectividad de inhibición de quinasa y propiedades farmacocinéticas； también se proporciona un método de preparación para los compuestos； también se proporciona una terapia de combinación que incluye los compuestos en combinación con otra composición de fármaco dirigido y otro fármaco； la terapia de combinación optimizada tiene un efecto cooperativo, inhibe la existencia de un tumor mejor que un solo fármaco dirigido, y provoca que ciertos tumores desaparezcan completamente； la terapia de combinación optimizada trata resistencia a fármac
